NLM Digital Collections

Search

Start Over Collections Health Policy and Services Research ✖Remove constraint Collections: Health Policy and Services Research Subjects United States ✖Remove constraint Subjects: United States Publication Year 2020 to 2021 ✖Remove constraint Publication Year: <span class="from" data-blrl-begin="2020">2020</span> to <span class="to" data-blrl-end="2021">2021</span>

1302. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, January 2020
Subject(s):
Biomarkers
Clinical Trials as Topic
Drug Approval
Drug Development
Drugs, Investigational
Hematologic Neoplasms -- drug therapy
Investigational New Drug Application
Neoplasm, Residual
Endpoint Determination
Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
Leukemia, Myeloid, Acute -- drug therapy
Leukemia, Promyelocytic, Acute -- drug therapy
Multiple Myeloma -- drug therapy
Patient Selection
Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
Prognosis
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

1303. Enforcement priorities for electronic nicotine delivery systems (ENDS) and other deemed products on the market without premarket authorization

Publication:
Silver Spring, MD : Center for Tobacco Products, January 2020
Subject(s):
Commerce -- legislation & jurisprudence
Electronic Nicotine Delivery Systems -- standards
Tobacco Products -- legislation & jurisprudence
Tobacco Products -- standards
Adolescent
Government Regulation
Product Labeling
Vaping -- prevention & control
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

1304. Belimumab and voclosporin for lupus nephritis: effectiveness and value : final report

Author(s):
Tice, Jeffrey A., author
Agboola, Foluso, author
Herron-Smith, Serina, author
Chapman, Rick, (Of Institute for Clinical and Economic Review), author
Pearson, Steven D., author
Mandrik, Olena, author
Thokala, P. (Praveen), author
Fotheringham, James, (Of University of Sheffield), author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 16, 2021
Subject(s):
Antibodies, Monoclonal, Humanized
B-Cell Activating Factor -- antagonists & inhibitors
Calcineurin Inhibitors -- therapeutic use
Cyclosporine -- therapeutic use
Immunosuppressive Agents -- therapeutic use
Lupus Nephritis -- drug therapy
Treatment Outcome
United States

1305. Treatments for anemia in chronic kidney disease: effectiveness and value : final evidence report

Author(s):
Mustafa, Reem A., author
Fox, Grace, (Of Institute for Clinical and Economic Review), author
Campbell, Jonathan D., author
Agboola, Foluso, author
Pearson, Steven D., author
Rind, David M., author
Bloudek, Lisa, author
Carlson, Josh J., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, March 5, 2021
Subject(s):
Glycine -- analogs & derivatives
Hematinics -- therapeutic use
Isoquinolines -- therapeutic use
Hypoxia-Inducible Factor-Proline Dioxygenases -- antagonists & inhibitors
Anemia, Iron-Deficiency -- drug therapy
Renal Insufficiency, Chronic -- complications
Renal Insufficiency, Chronic -- drug therapy
Treatment Outcome
United States

1306. Bempedoic acid and inclisiran for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: Effectiveness and value : final report

Author(s):
Lin, Grace A., author
Jih, Jane, author
Agboola, Foluso, author
Peason, Steven D., author
Kazi, Dhruv S., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, March 2, 2021
Subject(s):
Anticholesteremic Agents -- therapeutic use
Atherosclerosis -- prevention & control
ATP Citrate (pro-S)-Lyase -- antagonists & inhibitors
Dicarboxylic Acids -- therapeutic use
Fatty Acids
Hyperlipoproteinemia Type II -- drug therapy
RNA, Small Interfering
Secondary Prevention
Treatment Outcome
Drug Therapy Combination
Ezetimibe -- therapeutic use
United States